Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 18/20 | 0.84 |
| ▸ | OPRM1 | P35372 | 18/20 | 0.81 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.81 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.71 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270071 | 0.92 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL15794608 | 0.90 | OPRM1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL30455750 | 0.90 | OPRM1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL4546486 | 0.84 | OPRL1 (0.66) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL550242 | 0.84 | OPRL1 (0.63) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL1271622 | 0.84 | OPRL1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL3872453 | 0.82 | OPRM1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL853891 | 0.80 | OPRM1 (1.00) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL4546475 | 0.80 | OPRL1 (0.80) | OPRL1OPRM1OPRK1OPRD1OGFRL1 | |
| SCHEMBL13221443 | 0.79 | OPRL1 (0.60) | OPRL1OPRM1OPRK1OPRD1OGFRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110602-B2 | Compounds comprising heterocyclic-substituted piperidine for treating pain | PURDUE PHARMA L.P. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022519-A1 | HETEROCYCLIC-SUBSTITUTED PIPERIDINE COMPOUNDS AND THE USES THEREOF | TRPV1, P2RX4, TRPA1 | OPRL1 6/4885OPRM1 17/4885OPRK1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.